D-Cycloserine (DCS), a partial agonist at the glycine site of the NMDA receptor, was investigated as a potential neuroprotective agent for amyotrophic lateral sclerosis (ALS). The rationale stemmed from the hypothesis that modulating NMDA receptor activity could protect motor neurons from excitotoxic death, a key mechanism implicated in ALS pathogenesis.
This trial represented an important exploration of the excitotoxicity hypothesis in ALS, which proposes that excessive glutamate signaling through NMDA receptors leads to motor neuron degeneration. Unlike direct NMDA receptor antagonists, which had problematic side effects, D-cycloserine offered a novel approach through partial agonism at the glycine modulatory site.
| Parameter |
Details |
| Phase |
Phase 2 |
| Status |
Completed |
| Drug |
D-Cycloserine (DCS) |
| Dosage |
500-1,000 mg daily |
| Administration |
Oral, divided doses |
| Patient Population |
Adults with clinically definite or probable ALS |
| Duration |
12 months |
| Design |
Randomized, double-blind, placebo-controlled |
- Diagnosis of clinically definite or probable ALS (El Escorial criteria)
- Age 18-75 years
- Disease duration ≤5 years
- Forced vital capacity ≥50% predicted
- Ability to comply with study procedures
- Presence of other neurological diseases
- Significant cognitive impairment
- Psychiatric contraindications
- Previous D-cycloserine exposure
- Impaired renal function
D-cycloserine's proposed neuroprotective mechanisms involve multiple pathways:
-
Partial Agonist Activity
- Binds to the strychnine-insensitive glycine modulatory site
- Acts as a partial agonist with intermediate efficacy
- Produces submaximal receptor activation
-
Receptor Activation Properties
- Promotes receptor opening without causing excessive activation
- Avoids the excitotoxic effects of full agonists
- Maintains physiological signaling
-
Calcium Homeostasis
- Maintains physiological calcium signaling
- Prevents pathological calcium influx
- Supports neuronal survival pathways
The NMDA receptor is a glutamate-gated calcium channel:
-
Channel Properties
- Permeable to calcium and sodium
- Requires both glutamate and glycine for activation
- Voltage-dependent magnesium block
-
Physiological Function
- Synaptic plasticity and learning
- Neurodevelopment
- Excitatory signaling
-
Pathological Activation
- Excessive calcium influx
- Activation of cytotoxic pathways
- Oxidative stress and mitochondrial dysfunction
The neuroprotective mechanisms include:
-
Excitotoxicity Modulation
- Theoretical protection against glutamate excitotoxicity
- Submaximal activation may be protective
- Avoids the paradoxical excitation seen with antagonists
-
Synaptic Plasticity
- May enhance NMDA receptor-dependent synaptic plasticity
- Supports neuronal network function
- Potentially promotes compensatory mechanisms
-
Neurotrophic Effects
- Potential to support neuronal survival pathways
- May activate protective signaling cascades
- Could support remaining motor neurons
-
Optimal Dosing
- The relationship between DCS dose and NMDA receptor effects is complex
- Dose-response may be bell-shaped
- Individual variation in response
-
Receptor Desensitization
- Prolonged exposure may lead to receptor desensitization
- Effects may diminish over time
- Requires careful dose selection
-
Dual Effects
- Can act as agonist or antagonist depending on context
- Partial agonist properties allow modulation
- Context-dependent effects
The Phase 2 trial employed rigorous methodology:
-
Randomized, Double-Blind, Placebo-Controlled Design
- Participants randomized to D-cycloserine or placebo
- Double-blind to minimize bias
- Placebo run-in and treatment periods
-
Treatment Arms
- D-cycloserine at defined doses
- Placebo control
- Standard of care in both arms
-
Treatment Duration
- 12-month treatment period
- Regular efficacy and safety assessments
- Long-term follow-up
- Rate of decline in arm muscle strength
- Quantitative muscle testing
- Force generation measurements
- ALSFRS-R (Revised ALS Functional Rating Scale)
- Pulmonary function (FVC, vital capacity)
- Survival
- Quality of life measures
- Biomarker studies
- Pharmacokinetic assessments
- Subgroup analyses
| Visit |
Assessment |
| Screening |
Baseline demographics, ALSFRS-R, muscle testing |
| Baseline |
Randomization, final eligibility |
| Monthly |
Safety, efficacy assessments |
| Quarterly |
Full functional assessment |
| Monthly |
Pulmonary function |
| Endpoint |
Final comprehensive assessment |
Key findings from the trial:
-
Muscle Strength Decline
- No significant benefit in rate of muscle strength decline
- Primary endpoint not met
- Placebo and treatment groups similar
-
Quantitative Measures
- Arm muscle strength declined similarly in both groups
- No statistically significant difference
- Trend not favoring active treatment
-
ALSFRS-R
- No significant differences in functional decline
- Similar progression rates
- Quality of life measures comparable
-
Pulmonary Function
- Similar decline in FVC in both groups
- No protective effect observed
- Respiratory function unchanged
-
Survival
- No significant difference in survival
- Similar mortality rates
- Disease progression unchanged
-
Tolerability
- Acceptable tolerability
- Most adverse events mild to moderate
- Low discontinuation rate
-
CNS-Related Side Effects
- Dizziness and somnolence reported
- Some cognitive effects
- Generally manageable
-
Other Effects
- Gastrointestinal symptoms occasionally
- No significant hematological effects
- Renal function monitored
| Outcome |
Result |
| Primary endpoint |
Not met |
| Muscle strength |
No significant benefit |
| ALSFRS-R |
No significant difference |
| Survival |
No significant difference |
| Safety |
Acceptable tolerability |
The D-cycloserine trial contributes to understanding ALS pathogenesis and treatment development:
-
Challenges of Modulating Glutamate Receptors
- Complex receptor pharmacology
- Multiple downstream pathways
- Difficult to achieve neuroprotection without side effects
-
Glycine Site Approach
- Novel therapeutic target
- Partial agonist strategy
- Theoretical advantages over antagonists
-
Negative Trial Implications
- Excitotoxicity may not be modifiable via NMDA glycine site
- Alternative approaches needed
- Pathophysiology more complex than hypothesized
The trial informs the excitotoxicity hypothesis in ALS:
-
Complexity of Excitotoxic Mechanisms
- Multiple receptor types involved
- Non-NMDA mechanisms may be critical
- Cell-specific vulnerability
-
Therapeutic Implications
- Single-target approaches may be insufficient
- Combination strategies needed
- Earlier intervention may be required
-
Alternative Targets
- AMPA receptor modulation
- Glutamate transport enhancement
- Metabolic support
The trial provides lessons for ALS drug development:
-
Endpoint Selection
- Importance of appropriate outcome measures
- Need for sensitive detection methods
- Biomarker development needed
-
Target Engagement
- Need for biomarkers of target engagement
- Confirmation of mechanism of action
- Dose-finding optimization
-
Trial Design
- Enrichment strategies
- Biomarker stratification
- Adaptive designs
Excitotoxicity is a central concept in ALS[motor_neuron_death][glutamate_transport_als]:
-
Glutamate Excess
- Elevated extracellular glutamate in ALS
- Impaired glutamate transport
- Increased release, decreased uptake
-
Receptor Involvement
- NMDA receptor overactivation
- AMPA receptor toxicity
- Metabotropic receptor contributions
-
Calcium-Mediated Damage
- Excessive calcium influx
- Mitochondrial dysfunction
- Activation of apoptotic pathways
-
Intrinsic Factors
- High metabolic demand
- Large cell size with extensive connectivity
- Specific calcium-buffering properties
-
Environmental Factors
- Axonal length and complexity
- Neuromuscular junction demands
- Non-neuronal cell interactions
| Trial |
Mechanism |
Outcome |
Lessons |
| Riluzole |
Glutamate modulation |
Modest survival benefit |
First approved therapy |
| D-cycloserine |
NMDA glycine site |
Negative |
Alternative approaches needed |
| Ceftriaxone |
Glutamate transport |
Negative |
Translation challenges |
| Lithium |
Neuroprotection |
Mixed results |
Optimal dosing unclear |